Clinical Trial Update: Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial investigating erythropoietin in refractory autoimmune encephalitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Encephalitis

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Autoimmune Encephalitis | Phase 4 | Status: WITHDRAWN